<?xml version="1.0" encoding="UTF-8"?>
<p>Innovative MD and ATMP containing NBMs could address current unmet therapeutic or diagnostic needs, however they may be developed, manufactured and used in completely new ways compared with conventional medicinal technologies and this can challenge their market authorisation. Therefore, to properly support the translation of NBMs used in MD and ATMP into clinical use, careful assessment of their benefit-risk balance is required [
 <xref rid="B119-materials-13-04532" ref-type="bibr">119</xref>] and this task is covered by the benefit-risk analysis component of the RMF (right-side pillar, cf. 
 <xref ref-type="fig" rid="materials-13-04532-f001">Figure 1</xref>). 
</p>
